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Chapter 4 Trial design
1. Introduction to trial design
Trials should be designed to produce unambiguous estimates of the effects of interventions, which are precise enough
for public health planning. A common goal of all intervention studies, including trials, is to evaluate the effect of a
specific intervention (or a specific package of interventions) applied in a specific manner to a well-defined population.
In the trial design, the major issues will be: (1) the nature of the intervention, the strategy for its implementation, and
the natural size of the unit at which the intervention is applied (for example, individual, household, school, village,
district); (2) the likely effects, including possible adverse effects, and how they should be measured; and (3) the
comparisons that need to be made with other interventions.
In most LMICs, disease control is the responsibility of the Ministry of Health (MOH). Therefore, wherever possible,
the Ministry should be involved in the planning and monitoring of trials, and the results must be made available in
such a way that they are of direct relevance to national disease control activities (see Chapter 23). As the Ministry is
often the implementing agency for interventions in public health programmes, it is generally desirable that
independent investigators actually conduct the trials of interventions.
This chapter gives an overview of the main factors to consider in the development and implementation of health
intervention trials in LMICs.
1.1. Planning a trial
The trial planning process is a major exercise which starts, and which should be largely completed, before any field
activities have taken place, other than initial feasibility studies and small-scale pilot investigations (see Chapter 13).
The planning process should encompass all aspects of the trial, from formulation of detailed objectives, based on the
initial idea, through preparation for all field activities, collection of data, and analysis of results, to their publication,
dissemination, and potential use in disease control. The plan should also try to anticipate the form of any studies that
will follow, depending on the possible different outcomes of the trial.
Detailed planning is necessary for several purposes. First, information on the trial will be required by local and
national administrations for them to review as part of the trial approval process. A similar description will be required
by any agency that is going to review the proposal for funding. The detail required in such grant applications varies
greatly from agency to agency. Some require a comprehensive document with full details of all trial procedures, while
others put quite a small upper limit on the size of any application they are prepared to review. It is usually more time-
consuming to prepare the former kind of application, but the latter kind may present a more formidable challenge,
because, in relatively few words, the investigators have to present convincing evidence that they have considered and
worked out all issues that would have been included in the longer type of application. Advice on the preparation of
grant applications is given in Chapter 8.
A second reason for detailed planning at the start of an investigation is that possible problems must be anticipated in
advance and solutions thought through, in order to reduce the likelihood of the trial falling behind schedule or having
to be radically changed or abandoned, due to problems that could have been foreseen and avoided. Commonly,
funding agencies require a section on potential risks to the trial, in which the investigators are asked to specify what
could go wrong and the consequences this would have for the trial. It is rare to be able to predict all potential
problems, but the more that have been considered in advance, the smaller the chance of catastrophe.
Realistic estimates must be made of the resources needed (for example, for transport, staff salaries, allowances, items
of equipment) and the likely trial duration, including the time to analyse and report the trial, in order to be able to
calculate the required budget for the trial. Underestimating the support needed may jeopardize some of the objectives,
which may have to be revised or abandoned in the middle of the trial, whereas overestimating the cost may prejudice
the funding agency against agreeing to support the trial. It is tempting to underestimate costs in the hope of increasing
the chance of funding, but this may be self-defeating and, in any case, will often be picked up by the experienced
investigators asked to review the trial proposal by the funding agency. The time it will take to conduct and analyse a
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trial is also often underestimated, particularly for trials where implementation of the intervention, or package of
interventions, is not directly under the control of the evaluators but depends instead on the MOH or other partners.
Advice on the preparation of budgets is given in Chapter 18.
In the present chapter, the steps to be included in the trial plan are discussed in the approximate order that they would
arise, from the formulation of objectives through to the eventual publication, dissemination, and use of the findings. In
the remaining chapters, specific issues relevant to the planning process are reviewed in greater detail, and cross-
references are given in this chapter, where appropriate.
1.2. Ethical considerations in designing a trial
Ethical considerations impinge on many aspects of the design and conduct of trials and are discussed fully in Chapter
6. Briefly, any research investigation that involves human subjects should be submitted for ethics committee review.
Intervention trials in some communities in LMICs may pose specific ethical dilemmas. The dogma that an
investigator ‘should treat everyone in the trial as though they were a member of his or her own family’ is both
difficult to apply and often inappropriate in situations of extreme poverty, in which some trials in LMICs will take
place. Related issues concern the responsibility that an investigator has to those who live in the same community as
the trial subjects but who, for whatever reason, are not included in the trial, and what happens regarding the public
health use of an intervention after a trial has shown an intervention to be efficacious. Very commonly, an investigator
must walk a tightrope, balancing his or her responsibilities to the individuals in the trial with those related to the
potential of the interventions being evaluated to improve public health. The MOH knows these problems well, as they
are implicit in any allocation of the health budget between the various potential preventive and curative services, but,
commonly, the officials allocating the routine health budget are several steps removed from the individuals and
communities that their decisions will affect. The field trial researcher usually has to face these issues directly. There
are no simple solutions to these problems. It is important that each research study is subject to strict ethical review,
with due attention to the specific conditions in and under which it will be conducted.
1.3. Trial governance
Since the first edition of this book was published, there has been a much greater emphasis on trial governance and
quality control (QC) in trials. There are now extensive international guidelines on the governance of clinical trials, in
which the roles of bodies, such as the trial ‘sponsor’, the principal investigator (PI), the trial Steering Committee, and
the Data and Safety Monitoring Committee (DSMC), are discussed and defined. These aspects are considered in more
detail in Chapter 7.
2. Definition of trial objectives
Once an idea for a trial has been formulated, it will be necessary to detail the specific objectives of the trial. To do
this, the researcher will need to find out what has already been done regarding the evaluation of the intervention or
interventions of a similar kind. This may involve meeting or corresponding with those undertaking similar studies,
and it will almost invariably involve conducting a systematic literature review to find out what has been published
that is relevant (see Chapter 3).
With this background information, the objectives of the trial can be formulated. These should include the overall aim
or purpose of the trial, such as ‘to evaluate the efficacy of a specific microbicide gel for the prevention of HIV
infection in women’ or ‘to measure the impact of a breastfeeding promotion strategy on the incidence of diarrhoeal
diseases in infants’. The specific objectives give more detailed statements of the particular questions that the trial is
designed to answer, or the hypotheses that it will test. Finally, a list of subsidiary objectives may be given which relate
to issues which are not central to the overall objectives but about which information will also be gathered while the
trial is in progress.
2.1. The idea for a trial
One of the most creative phases of the planning of a trial is the selection of the subject area of the research and the
formulation of the specific questions that will be addressed. A major motivation for most successful researchers is that
they are doing something that they really enjoy and are researching questions about which they feel passionate. Their
motivation may come from scientific curiosity about the causes or treatment or control of a particular disease, or
about the effects of a specific intervention, or their concern may be to explore different ways that health or social
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systems can improve the public health. The field researcher may be motivated by working directly with people in their
communities and be stimulated by the challenges posed by working in remote or difficult situations, outside of the
hierarchy that may exist, for example, in a hospital environment.
The development or refinement of an idea for a field trial should take place in interaction with others at local,
national, and possibly international levels. The research activity must not only be acceptable to the population in
which it will be undertaken, but also to those who will authorize it nationally and to those who will fund it. Most good
ideas for field research on the control of a disease that is of public health importance are likely to attract support.
Field research likely to receive the highest priority, both nationally and internationally, is that directed at control of
diseases of greatest public health importance. An important preliminary to the development of a research proposal on
a specific disease or condition may be a survey in the local community to determine the importance of the disease of
interest. Such local data might be presented side by side with estimates of the global burden of disease attributable to
the condition being studied.
The progress of science (and of public health) is not only dependent on groundbreaking first trials that show that a
new intervention can be effective in one context. Progress also requires the replication of such trials in different
settings to determine whether the findings from the original trial may be generally applicable. Replications of trials of
bacille Calmette–Guérin (BCG) vaccination against TB and leprosy and of rotavirus vaccines, for example, have
shown substantial variations in the efficacy of the vaccines in different parts of the world. This is even more important
for effectiveness trials of interventions that are delivered through routine services where results may show important
variations from one location to another, due to contextual differences. Although sometimes disparagingly called ‘me
too!’ trials, such confirmatory (or otherwise!) trials are very important for the assessment of the public health
usefulness of an intervention in a specific context.
A trial may either test for superiority or for equivalence. The choice will depend on the nature and effectiveness of the
comparison intervention and has important implications for the choice of trial size (see Chapter 5). For example, if the
aim is to test whether a new drug for the treatment of visceral leishmaniasis is more effective than the standard drug
treatment, this will require what is called a ‘superiority’ trial. However, it could be that the new drug is much cheaper
or is thought to have fewer side effects. If this was confirmed in a field trial, it would be likely to be adopted even if it
was no more effective than the standard drug, so a trial that is designed to test for ‘non-inferiority’ or ‘equivalence’
would be appropriate.
2.2. Trial purpose
The statement of the purpose of a trial (termed ‘goal’ by some agencies) should convey to the reader the type of
intervention, or package of interventions, to be evaluated (without details of how it will be applied, dose, and so on)
and the endpoints against which the impact will be measured, without necessarily specifying the magnitude or precise
nature of the impact expected or which the trial will be designed to detect. It may also include a description of the
ways in which the results of the trial may influence public health policy and contribute to scientific knowledge. For
example, in a trial of the use of the drug ivermectin against onchocerciasis, the statement of the purpose might be ‘to
assess the impact of mass treatment with ivermectin on the transmission of onchocerciasis and to measure any side
effects in those treated with the drug’. For a trial of a new vaccine against the blood stages of the malaria parasite, the
purpose may be ‘to measure whether a Plasmodium falciparum asexual blood stage vaccine reduces episodes of
clinical malaria’. For a trial to test the effect of cash payments conditional on girls either staying in, or returning to,
secondary school on their risk of HIV infection, the purpose might be ‘to assess whether educational conditional cash
transfers reduce acquisition of HIV infection in girls’. Finally, for the example of the equivalence trial of a new drug
for visceral leishmaniasis treatment, the purpose might be ‘to test whether the new drug is at least as effective as the
standard treatment for treatment of visceral leishmaniasis’.
2.3. Specific objectives of the trial
In the specific objectives (called specific aims by some agencies), a quantitative statement should be made regarding
the size of the effect of an intervention that a trial is designed to detect and the precision with which the effect will be
measured. Such specifications are necessary in order to calculate how large a trial should be, using the methods
described in Chapter 5. The nature of the intervention should be given in more detail than in the statement of purpose
(for example, dose and frequency of administration), and the endpoints of the trial clearly stated. They should also
include a specification of the size of the trial and detail the population in which the intervention will be applied. For
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the example of the trial of ivermectin against onchocerciasis, the specific objectives would include a statement of the
size of the impact on transmission which the trial would have a reasonable chance of detecting and the frequency with
which adverse reactions of different kinds would have to occur to be detected in the trial, while, for a malaria vaccine,
a more detailed description of the formulation of the vaccine would be required and statements included on the
magnitude of the true effects on the incidence of malaria that the trial would be very likely to detect as being
statistically significant. Finally, for the conditional cash transfer trial (see Section 2.2), the specific objectives should
state the size of payment, to whom it will be given (for example, to the girl herself, her parents, or some combination
of the two), the age range of the girls in the trial, and the size of effect on HIV incidence that the trial would have a
reasonable chance of detecting.
The proper specification of the specific objectives is crucial to a successful trial. They should include a concise, but
detailed, description of the intervention to be evaluated, the outcome(s) of interest, and the population in which the
trial will be conducted. The more specific and detailed the objectives are, the clearer it will be how to design a study
to meet them. It is crucial to set appropriate objectives, and it is worth spending time to get these both correct and
unambiguous.
2.4. Subsidiary objectives of the trial
In the context of many trials, there will be secondary endpoints which will be measured in the trial but which are not
the prime purpose for which the trial is conducted. Also substudies may be included, having subsidiary objectives,
such as the comparison of various serological tests or the analysis of genetic markers and their correlation with
disease. It may be decided to add other objectives on to an intervention trial which do not relate to the main
objectives. In the trial of ivermectin against onchocerciasis, for example, the impact on some other parasitic diseases
might be assessed.
To increase the plausibility of trial findings, it is important to document changes in intermediate outcomes, which are
directly related to the outcomes of principal interest, whenever this is possible. This requires laying out an ‘impact
model’ (see also Chapter 15), describing how the intervention is expected to lead to the major outcome being studied.
For stand-alone biological interventions, these models tend to be quite simple. For example, a trial of the effect of
periodic vitamin A supplementation on child mortality should document that the vitamin A status improved in
children receiving the supplement, but not in the comparison group. Impact models for non-biological interventions
are often more complex. For example, in the conditional cash transfer trial, the impact on retention in secondary
school and school achievement grades or the impact on reported sexual risk behaviours or on the incidence of other
STDs or of pregnancy could also be studied, as well as the primary endpoint of HIV incidence. Impact models are
essential for deciding which intermediate indicators must be measured.
The introduction of an intervention may also provide a special opportunity for determining particular key factors in
the pathogenesis of disease. For example, trials of ivermectin, a microfiliaricide, against Wuchereria bancrofti may
provide evidence for the role of microfilaria, as compared to that of adult worms, in the pathogenesis of lymphatic
filariasis disease. Decisions to add on studies of this kind should not be taken lightly, as they will invariably need
additional commitment of resources and may involve the trial population in additional inconvenience. They may thus
have a negative impact on the primary objectives, perhaps by overstretching the trial team’s technical or managerial
resources, and the final ‘cost’ to the trial may be much greater than it appeared to be in purely monetary terms.
Once a large field trial is successfully under way, it is not unusual for the trial organizers to be approached by other
investigators who wish to graft on additional procedures to answer questions of interest to them. There may be
considerable value in utilizing the same trial for multiple purposes, but full consideration should be given to the extra
work that this will entail, especially for key members of the research team, and to other possible harmful effects such
as upsetting the rapport between the trial team and the trial population.
3. Selection of interventions
3.1. Intervention characteristics required
Several criteria should guide the suitability of candidate interventions to be evaluated in a large-scale field trial. The
intervention, or package of interventions, should usually be one that could be introduced into a national or regional
disease control programme (though this criterion might not apply for ‘explanatory’ or ‘proof of principle’ trials—see
Chapter 2, Section 3.3). The dose (when applicable) should be ‘optimal’. Evidence would usually be required from
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smaller preliminary studies (sometimes called Phase I and II trials, particularly with respect to trials of drugs and
vaccines) that the intervention is relatively safe and produces a convincing intermediate response, such as a good
antibody response to a vaccine or a change in self-reported sexual behaviour for an intervention to prevent unwanted
pregnancies.
When an intervention has to be repeated several times to be effective (for example, micronutrient supplements), there
should be evidence that the interval between each intervention is appropriate. For some interventions, the concept of
dose is meaningless, such as the application of a diagnostic or screening test. Corresponding relevant evidence would
then be required that the test is adequate (for example, previous studies indicating that it had good sensitivity,
specificity, and predictive values). For continuous or repeated treatments, similar considerations apply to the duration
of treatment. For example, with vitamin supplementation, the duration required will depend on whether the outcome
of interest is the reversal of the acute effects of severe deficiency or of the chronic effects of more moderate
deficiency. In addition to being safe and giving promise of being efficacious, the intervention must be acceptable to
those to whom it is directed, relatively easy to deliver, and, at least eventually, of sufficiently low cost that it could be
incorporated into the national disease control strategy if it is proved to be effective within the field trial.
3.2. Number of interventions compared
The choice of the number of different interventions to compare in a field trial is likely to be determined not only by
the number of competing alternatives, but also by the implications the choice has on the size of the trial. This, in turn,
is dependent on the frequency with which the outcome of interest occurs. ‘Rare’ outcomes require large trials (as
discussed in Chapter 5). For example, in a trial of leprosy vaccines in South India, it was planned that each ‘arm’ (one
of the alternative intervention assignments) included in the trial would require around 65 000 trial participants, in
order for the trial to have the desired statistical power to detect effects that would be of public health importance
(Gupte et al., 1998). Clearly, in this situation, a decision to add another arm would have had enormous cost and
logistic consequences.
If the outcome is common, however, trials to compare more than two interventions may be undertaken more readily.
For example, if seroconversion following vaccination is the outcome of interest, it may be straightforward to compare
multiple vaccines or vaccination strategies in a single trial.
It is important to note, however, that many researchers try to build too many comparisons into a trial. There is often a
tendency to divide groups after the sample size has been calculated or to plan comparisons within groups, without
going through the appropriate computations (as given in Chapter 5).
Comparisons within a single trial can always be made with much greater confidence than those between trials. Thus,
if drug A is found to be 50% more effective than a placebo in one trial and drug B is found to be 50% more effective
than a placebo in another trial, it will not necessarily be possible to conclude that A and B are equally effective, as the
circumstances in which the two trials were conducted will not have been identical. A further trial may be necessary
for a direct comparison of A and B. If the need for this trial could have been anticipated in advance, it would have
been more efficient to conduct one trial involving both drugs A and B and a placebo. A trial like this may be more
complex to organize and would probably have to be substantially larger than either of the ‘2-arm’ trials but would still
tend to be smaller than the sum of the two trials.
When two interventions are being compared to a control intervention, and in situations where it would be possibly
appropriate to apply both interventions to the same individual (or community), an efficient way of comparing both
interventions with the control arm in the same trial is to design it as a ‘factorial’ trial. In such trials, some individuals
receive the control intervention, others receive one or other of the new interventions, and some receive both
interventions (typically 25% in each of four groups) (Montgomery et al., 2003). Although not commonly used, this
design is very efficient, unless there is ‘interaction’ between the two interventions, i.e. the effect of both interventions
applied at the same time is different from the simple sum of the separate effects of each of the interventions. Ayles et
al. (2008), Awasthi et al. (2013a), and Awasthi et al. (2013b) are examples of the design of such trials.
3.3. Combined interventions
For some diseases, there are several possible interventions that may reduce the disease impact on a population. For
example, interventions against malaria include destruction of mosquito breeding sites, spraying of residual insecticide,
personal protection measures (for example, use of bed-nets and repellents), drug prophylaxis, and drug treatment, and
trials might be designed to evaluate each of these interventions individually. A malaria control programme may
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choose to use more than one intervention at the same time and may wish to evaluate the impact of the ‘package’ of
interventions, rather than the individual components of it. In such a case, the trial might compare an integrated
strategy incorporating several different interventions applied simultaneously with a control group in which only the
routine interventions that were previously available would be applied.
Several trials of this kind have been conducted for the prevention of HIV. For example, a recent trial in Tanzania
tested the effectiveness of a package of interventions targeted to young people. Those in the intervention group
received HIV prevention education in school; health workers in their local health facilities were given special training
and support to try to make their facilities more ‘youth friendly’; new suppliers who were thought to be particularly
attractive to young people were trained and supported to sell condoms, and annual ‘youth health weeks’ were
organized in their local communities (Ross et al., 2007). The advantage of this kind of trial is that it allows the testing
of a package on interventions that might reasonably be expected to have a greater impact than any single component
of the package. However, if no effect is seen, then although it may be reasonable to conclude that no one of the
components of the intervention (at least, as applied in the trial) would have been effective on its own, it is necessary to
think carefully about whether the existence of several concurrent interventions might have diluted the effect of one
component on its own, or even that one component might have counteracted the effect of another. Another
disadvantage is that, if an effect is demonstrated, it is not possible to be sure of the contribution to the overall result of
each of the various components of the intervention.
3.4. Choice of comparison intervention
The best way to evaluate an intervention is to compare its effect with that of another intervention in the same
population at the same time. Whenever possible, the allocation of individuals or groups of individuals to the different
interventions should be ‘at random’ (see Section 4.1 and Chapter 11). In general, the intervention that is the current
‘best’ should be used as the comparison, but the choice of the ‘control’ intervention is not always straightforward and
may involve difficult ethical considerations (see Chapter 6). When no effective intervention is known, the comparison
must be with a group in which ‘no intervention’ is made; ideally, a placebo should be administered in order to
preserve ‘blinding’ (see Section 4.1). For example, before the development of ivermectin no effective and safe
treatment for onchocerciasis existed. Thus, placebo-controlled trials of the drug were ethically acceptable, at least
until the beneficial effects of ivermectin had been established. For most tropical diseases, however, some kinds of
intervention already exist and may already be deployed by the health services or by a control programme in the area
where a trial is planned. Only in very rare circumstances would it be ethical to withdraw these existing interventions
for the purposes of a trial. A more complex issue is with respect to the extent to which they should be introduced in
the context of a trial. It is known that regular prophylaxis with anti-malarial drugs reduces morbidity from malaria, for
example, so would it be necessary to give this intervention to all those in the ‘control’ arm of a malaria vaccine trial,
even though, in normal circumstances, very few, if any, of them would otherwise have been on prophylaxis? Indeed,
would it even be ethical to withhold prophylaxis from those who would be receiving a malaria vaccine whose efficacy
was unknown? The optimistic reader will seek a definitive answer to these questions in Chapter 6! Unfortunately, the
search will be in vain, as there are no general definitive solutions to problems such as this; each situation has to be
considered on its own merits, taking full account of the circumstances in which a particular investigation is planned.
However, in Chapter 6, key principles are outlined that should be used when making such judgements.
In a leprosy vaccine trial in Venezuela, the new leprosy vaccine consisted of a mixture of BCG and killed
Mycobacterium (M.) leprae bacilli. When the trial was designed, a choice had to be made between using BCG for the
control arm (the efficacy of BCG alone against leprosy in Venezuela was unknown at the time) or using a placebo.
BCG was chosen, even though doing this might reduce the chance of showing a protective effect (as BCG alone may
have been protective). The inclusion of a third, placebo, arm would have allowed the protective effect of BCG alone
to be evaluated, but the incidence of leprosy was too small for a third arm to be feasible within the trial. The major
purpose of the trial that was conducted was therefore to evaluate whether a leprosy-specific vaccine (i.e. one which
included M. leprae bacilli as well as BCG) was more effective than a non-specific vaccine (in this case, BCG). If the
comparison had been with a placebo instead of BCG, any effect due to BCG could not have been distinguished from
that due to the addition of M. leprae bacilli to the vaccine. In a larger trial of the same vaccine that was conducted in
India, it was possible to include a placebo arm (Gupte et al., 1998).
The use of a placebo may be very important to derive an unbiased measure of effect (see Section 4.1 and Chapter 11,
Section 4), but it requires careful ethical justification, and thought must be given to whether particular circumstances
might lead to treatment being offered to participants, irrespective of their trial arm. In a placebo-controlled trial of





vitamin A supplementation in Ghana, for example, the objective was to determine if a reduction of child mortality
was produced by supplementation. As eye signs of vitamin A deficiency are effectively treated by vitamin A
supplements, all in the trial were monitored for such signs and treated immediately if such signs were detected, even
though this was likely to reduce the power of the trial to detect an impact of vitamin A supplementation on mortality.
A related issue concerns trials which do not test new interventions as such but evaluate new ways of delivering
existing interventions. In a cluster randomized trial in Bangladesh, the Integrated Management of Childhood Illness
(IMCI) strategy promoted improved ways of delivering interventions such as antibiotics for pneumonia, oral
rehydration therapy, and vaccines; these interventions were also available from routine services in comparison areas.
It was judged ethical not to change routine practices in the comparison areas, because these reflected what was
already in place in the country as a whole (Arifeen et al., 2009).
3.5. Complex interventions
The design of a trial to evaluate the efficacy of a new vaccine or drug is relatively straightforward, in the sense that
there are many past examples of such evaluations to draw upon when planning a new trial. However, the evaluation of
some interventions, such as the deployment of a new procedure in the health service or public health practice, may
involve consideration of several interacting components, including, for example, educational components and
behavioural change. Such interventions pose special problems for evaluation, and these kinds of intervention have
been called ‘complex’. Many of the extra problems relate to the difficulty of standardizing the design and delivery of
the interventions, their sensitivity to features of the local context, the organizational and logistical difficulty of
applying experimental methods to service or policy change, and the length and complexity of the causal chains
linking intervention with outcome. See Chapter 2, Section 2.3.4 and the associated Box 2.1 for further discussion.
4. Allocation of interventions within the trial
4.1. Randomization and ‘blindness’
Once a potential intervention has been shown to be safe and acceptable for use in humans and the dose schedule
established, trials should be conducted to evaluate quantitatively the benefit attributable specifically to the
intervention under trial, compared to some other intervention, while attempting to exclude the confounding effect of
other variables. The best way to exclude the potential effects of other factors—both those already known to be
confounders and also those that are confounders but are not known to be so—is to base allocation decisions as to
which intervention is applied to a particular individual, or group, on a random process. Incorporation of
randomization into the trial is an extremely important design issue (see Chapter 11).
The randomized intervention trial is as close to a rigorous scientific experimental study involving human beings as it
is possible to achieve ethically. The main study design features of a randomized trial are:
to avoid bias in assignment to the alternative interventions, all eligible trial participants should be assigned at
random to the alternative treatment groups. This involves two steps; the first is selecting participants on the basis
of the pre-established criteria for eligibility, and the second is the randomization procedures should ensure that
each eligible participant has the same chance of receiving a particular intervention procedure
to avoid bias in the assessment of the trial endpoints, whenever possible, the person(s) assessing the outcome
measures should not know to which intervention group the participant was assigned (i.e. the assessor should be
‘blind’ to the intervention group)
to avoid bias in the behaviour or reporting by the participant, whenever possible, the participant should also be
‘blind’ (i.e. the intervention group assignment should not be known by the participant).
If neither the assessor nor the participant is aware of the intervention allocations, the trial is said to be ‘double-blind’.
If only the assessors (or, more rarely, only the participants) are aware of the allocations, the trial is called ‘single-
blind’. For situations in which there is no known effective treatment or preventive method, a placebo of some sort
must be used if double-blinding is to be assured. The ‘double-blind’ approach is the key to the elimination of bias in
the assessment of the impact of an intervention, and, wherever possible, a ‘double-blind’ design should be used.
Sometimes it is not possible because of the nature of the intervention procedure, for example, where participation in
health education sessions is being compared to no intervention, or where cervical surgery is being compared to drug
treatment for cervical cancer. But even if the providers of the intervention must know the assignments, the person who
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assesses the trial outcome should be kept ‘blinded’, if feasible. The more clearly defined and objective the outcome to
be measured, the less critical it becomes to ensure blinding of the assessor. For example, as long as there is complete
ascertainment of all deaths in all arms of the trial, blindness is unlikely to be important in a trial with mortality as the
endpoint. Similarly, the less likely a patient is to be influenced by knowledge of which intervention they have
received, the less important their blinding is.
4.2. Unit of application of the interventions
Different interventions can be applied either to an individual or groups of individuals, such as everyone in a family or
household, everyone working in a particular company, or everyone in the community. The unit for randomization
should usually vary in parallel with this. The choice of the unit for application of the intervention depends upon the
nature of the intervention, the administrative method for its application, and the purpose for which the intervention is
being applied. In statistical terms, the most efficient design, in most circumstances, is to use the individual as the unit
of application, and this should be the design of choice, unless there is good reason for household or community
(group) application and randomization. There are four main reasons for applying an intervention to a group, rather
than by individual.
First, group allocation is appropriate when, by its nature, the intervention must be applied to everyone in the group
such as all those living in a geographical area, workplace, school, or community. Examples include most
environmental alterations and many vector control interventions. It also applies to many educational or health
promotion interventions which, although they can be delivered at individual level, are likely to spill over or
‘contaminate’ other individuals living in the same community.
Second, it may be logistically easier to administer the interventions to groups, rather than on an individual basis.
Sometimes it is administratively simpler and/or more acceptable to randomize by household or village, rather than by
individual. Furthermore, with individual randomization of medications, for example, there may be a risk of
individuals sharing medications within households or villages.
Third, if the purpose of applying the intervention is to reduce transmission of infection by a parasite, for example, the
appropriate unit of application would be the ‘transmission zone’, i.e. the area in which people (and, where
appropriate, vectors and intermediate hosts) may be interacting and sharing a common pool of parasites. Factors of
importance in defining such zones may include the flight range of vectors and the movements of people, vectors, and
intermediate hosts. To reduce interchange (‘contamination’) among transmission zones, it may be useful to have
intervening buffer zones that are not involved in the trial. For many diseases, however, the size of the transmission
zones may be difficult to determine and may vary over time.
Some interventions may be applied to individuals, but with the expectation that there may be an effect on
transmission, through applying them to a high proportion of individuals in the community, that goes beyond the effect
that would be achieved directly within the individuals who received the intervention (for example, through ‘herd
immunity’). The extent of coverage required to produce such effects depends upon the epidemiological circumstances,
the presence of other control measures, and the type of intervention being introduced. For example, the use of a
malaria vaccine to reduce the transmission of malaria in parts of Africa where the disease is ‘holoendemic’ may
require so near to complete coverage that such a purpose would not be seriously considered. However, in other parts
of Africa where the disease is much less prevalent, achieving high coverage with a highly effective vaccine might be
sufficient to interrupt transmission.
For some types of intervention procedures, when the procedure itself provides individual benefit, such as ivermectin
in the treatment of onchocerciasis, a further important issue is whether reduction of transmission provides a benefit, in
addition to the individual reductions of morbidity/mortality. Trial designs to demonstrate this additional benefit are
likely to be complex.
A fourth reason for applying interventions to a group or community as a unit would be for trials involving an
intervention of already proven efficacy in individuals, but for which the delivery may be more effectively carried out
on a group or community basis. The trial might consist of a comparison of different delivery systems. Generally, the
end result desired in this type of trial is based upon cost-effectiveness criteria. Here the question would be whether it
is possible to achieve a greater disease reduction for a given expenditure (or alternatively the same disease reduction
for less expenditure) by use of a community-based distribution system than by the usual individual distribution
methods. Many types of community-based distribution systems require community participation studies. The basic
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principles involved in community participation studies and in cost-effectiveness studies are described in Chapters 9
and 19, respectively.
When group randomization is adopted, the efficiency of the design can be improved by ensuring that the groups
allocated to the different intervention arms are as similar as possible with respect to risk factors for the outcomes of
interest, in the absence of the intervention. In other words, there is ‘balance’ between the risks of the outcomes of
interest between the trial arms. When there are large numbers of units to be allocated, randomization itself will ensure
comparability, but usually when communities or other groups are the units to be randomized, the number of units is
relatively small, and randomization may leave considerable differences between the groups in the different arms.
Attempts can be made in the analysis to allow for these differences, but the persuasiveness of the results may be
reduced if the conclusions depend upon extensive statistical manipulation of the trial results. A more efficient
approach to increase the comparability of the groups in the different arms is to stratify the groups into ‘blocks’ having
similar underlying pre-intervention risks of the disease outcome in question and to randomize within each block.
Stratification should be either in terms of variables which are strongly related to the risk of the outcome under study
or in terms of this risk itself. For example, in trials of interventions against malaria in which villages are to be
randomized, the villages might be stratified according to their pre-trial malaria prevalence or incidence rates, if such
information is available, and the randomization done within each of these strata. An extreme type of stratification is
when each ‘block’ includes the same number of groups (for example, villages) as there are arms of the trial, with each
village within each ‘block’ having similar malaria rates. One village in each block is then randomly allocated to each
intervention (see also Chapter 11, Section 3).
An alternative to stratification, when the number of available units for simple randomization, or even for stratification,
is too small, is known as ‘constrained’ or ‘restricted’ randomization. Assume there are 20 villages to be randomized.
All possible combinations of ten versus ten villages are evaluated, and only those combinations with good baseline
comparability between the two sets of villages are selected. Next, one of the shortlisted combinations is chosen at
random, and one of the two sets of ten villages is randomly selected to become the intervention group (Moulton,
2004). An example of the use of this approach is given in Sismanidis et al. (2008). See also Chapter 11, Section 3.3.
Often, good information on the distribution of the outcome measures will not be available in the trial population. In
such circumstances, baseline studies to obtain the required information should be considered. Sometimes, as an
alternative, surrogate measures must be used (i.e. measures which are thought to correlate closely with the outcome
measures of principal interest). In the absence of detailed data on the population, geographical proximity and socio-
economic level may be used as stratification characteristics. Thus, if a small geographical area is chosen as the
randomization unit, the total trial area would be divided into regions containing a small number of relatively
homogeneous units and, within each region, an equal number of units allocated to each treatment arm.
4.3. ‘Stepped wedge’ design
The issue of the ethics of randomization is presented in acute form in situations where previous studies, perhaps using
short-term endpoints or a more intensive intervention than is feasible on a population basis, indicate that the
intervention is likely to be beneficial. Withholding the intervention from those in one of the treatment arms for the
duration of the trial may then be argued to be unacceptable. Also, some individuals or organizations have an inherent,
if irrational, distrust of randomization, worrying that it is ‘experimentation’ (which of course it is!) or even ‘treating
humans like laboratory animals’. Such positions can make it impossible for a straightforward RCT design to be
accepted. An approach that can be adopted in this situation is the phased introduction of the intervention on a group-
by-group basis, until the entire target population is covered. In order to avoid bias, the order in which the groups are
given the intervention should be randomized and the number of groups should not be too small—at least six,
preferably many more. This approach was first used in The Gambia to evaluate the long-term effects of vaccination
against the hepatitis B virus (HBV) (The Gambia Hepatitis Study Group, 1987). A recent example of this design was
a trial in Ghana to evaluate the impact on child mortality of treating fever using anti-malarials, with or without also
treating with antibiotics (Chinbuah et al., 2012). Other examples are given in Brown and Lilford (2006).
The trial design is illustrated in Figure 4.1. This type of design has been called a ‘stepped wedge’ design. The power
of this approach, compared to a simple allocation of groups to one or other treatment arms, is of the order of 75–80%,
depending on the number of groups. The same considerations apply to stratification and blocking, as in the static
allocation designs.
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In the trial in The Gambia, hepatitis B vaccine was introduced into the routine child vaccination programme over a
period of 4 years. The order in which the different vaccination teams (there were 17 at the time the trial was planned)
began to use the vaccine was random. At the end of 4 years, there was a cohort of children who had received the
vaccine and a cohort who had not. These cohorts are being followed to compare the incidence rates of liver cancer and
chronic liver disease. At the end of the 4 years, all vaccination teams had started vaccinating children, so subsequent
cohorts of children were vaccinated. This phased introduction of the intervention mimicked the way in which many
public interventions are introduced, but the key feature of the random order of the introduction of the intervention
across the ‘clusters’ (in this case, vaccination teams) brought the crucial benefit of reducing the potential for the trial
producing biased results.
4.4. Other approaches to allocation of the interventions
The allocation of interventions to individuals based on a random scheme is the best approach to rigorously exclude
the potential biasing effects of other factors. However, non-randomized designs are often used. For example, a
common approach is the ‘before–after’ or ‘pre–post’ design, in which the incidence or prevalence of the disease under
study is compared before and after the intervention has been applied, and an attempt is made to attribute any
difference to the effect of the intervention. This approach has important limitations as it may be wrong to assume that,
in the absence of the intervention, the disease rate would have remained the same. Many diseases, and especially
those of parasitic or infectious origin, vary greatly in incidence and severity from year to year and place to place, for
reasons that are incompletely understood. Certainly variations in climate (for example, temperature and rainfall) can
have profound effects. Some diseases show marked declines (or increases) over time in some communities (for
example, TB and malaria), and sometimes these cannot be predicted in advance, or even related to any obvious
specific factor. ‘Before and after’ evaluations of interventions in such situations may be very misleading. Also, it is
not uncommon that the methods used to ascertain the trial outcomes change over time, either in terms of the actual
data collection method or the person or organization doing the data collection changes, and the two produce
systematically different results.
Another commonly employed approach is to apply an intervention in one community, and not in another, and to
attribute any difference in disease rates between the two communities as being due to the intervention. This also may
be very misleading, as a change may have occurred in one community, but not in the other, for reasons that had
nothing to do with the intervention. Random, rather than purposive, allocation of the intervention to one of the two
communities does not make any difference to this.
The commonest reason that is advanced for using a non-random allocation between intervention groups is for
simplicity of design and administrative ease. Approaches like these also seem easier to explain to officials and to gain
public acceptance. The rationale for randomization is difficult to communicate, even to other scientists, but the
arguments in favour of randomization, as outlined in Section 4.1, are extremely strong, and failure to accept this
approach has frequently led to studies from which erroneous conclusions have been drawn.
There are, however, situations in which allocation cannot be made on a randomized basis. There are occasions when
the benefits of an intervention appear so clear that a properly randomized trial cannot be contemplated, or when the
intervention or package has already been subjected to randomized trials and is being scaled up under routine
conditions. The value of the intervention then has to be assessed by comparison of the situation before and after its
introduction, or by the use of case-control studies after the intervention has been introduced (Smith, 1987). Although
before vs after studies suffer from the major limitations described earlier in this section, the plausibility of the trial’s
conclusions can be increased by trying to rule out alternative reasons why the changes might have occurred (Bonell et
al., 2011; Victora et al., 2004). First, if possible, data should be collected on more than one occasion, both before and
after the intervention is introduced (sometimes called a time-series study). This allows checking that the outcome of
interest was not already declining at the same rate prior to the start of the intervention, and that any decline after the
intervention was introduced was consistently present, rather than only there at one time point. Second, a comparison
should be made with time trends in disease rates in neighbouring populations where the intervention or package of
interventions has not been delivered, and/or in the country or region of the country as a whole. Third, the sharpness
with which changes in disease rates take place should be consistent with what might be reasonable to expect from the
intervention and related to the speed with which the intervention is introduced over the entire population. Fourth,
knowing and recording possible confounding variables in the before and after periods or in the populations being
compared in a non-randomized study may also aid interpretation of differences. For example, in a study in which an










objective is to reduce transmission of lymphatic filariasis by treating the human population with antifilarial drugs,
monitoring the vector population for changes in density and infectivity might be undertaken.
While acknowledging these exceptions to the use of randomization as the basis of allocation, such studies do not have
the rigour of a randomized design, and any conclusions drawn from them must be viewed with some caution. It is
reasonable to think of there being a hierarchy of evidence from intervention studies, with (1) well-designed and well-
conducted RCTs providing the strongest evidence, followed by (2) quasi-experimental studies, in which there is a
similar contemporaneous comparison group, but the receipt of the intervention has not been allocated randomly, and
then (3) non-experimental designs, in which there is no similar, contemporaneous comparison group such as the
before–after, time-series, or after-only designs outlined earlier in this section. Formal guidelines have been developed
by the GRADE working group (Guyatt et al., 2008) (<http://www.gradeworkinggroup.org>) to rank the quality of
evidence on the effect of an intervention, based on different kinds of study, ranging from the RCTs, which are judged
to provide the highest quality of evidence (if properly conducted), through to other kinds of study, providing lower-
quality evidence, including observational studies. The WHO has now adopted these guidelines and attempts to
undertake a formal grading of the quality of the evidence, with respect to policy recommendations they make
regarding specific interventions. The main focus of this book is on RCTs.
5. Choice of outcome measures and trial duration
For many interventions, there will be a range of outcomes that could be affected and which might be of interest to
study (see also Chapter 12). Nutritional supplements, for example, might affect any or all of the following:
biochemical measures
short-term acute consequences of deficiency
the consequences of chronic deficiency
mortality due to the specific causes of death that the intervention is intended to rectify
total (all-cause) mortality.
In determining which outcome is of the greatest importance for the trial, consideration must be given to whether:
the outcome is of clinical or public health importance
the probable effect on that outcome is large enough to be of clinical or public health interest
it can be accurately measured.
A substantial impact on total and age-specific mortality rates is always of public health importance, and systems can
usually be set up to ensure that they are well recorded (even though such systems often require considerable input if
they are not already in place), but they are unlikely to be sufficiently affected by most interventions to enable effects
to be detected with studies of manageable size. Mortality from the specific causes that the intervention is designed to
reduce should be more greatly affected, of course, but is usually much more difficult to measure accurately. In most
low-income settings, routine reporting of births and deaths by medically certified cause of death is not available or is
very incomplete and therefore potentially misleading. In these circumstances, measuring cause-specific mortality rates
will require interviews with close relatives or friends of the deceased to try to ascertain the signs and symptoms
preceding death, so that an attempt can be made to assign a likely cause of death. Such interviews are known as
‘verbal autopsies’. The International Network for the Demographic Evaluation of Populations and Their Health in
Developing Countries (INDEPTH) has produced model verbal autopsy questionnaires (<http://www.indepth-
network.org>). Using total mortality as the trial outcome, however, will dilute the effect that might be seen if specific
causes were examined, since the variation in deaths due to the unaffected causes is included. The choice may have to
be made between setting up special mechanisms to collect high-quality information on the cause of each death or to
allow for a dilution of the observed effect by increasing the size of the trial. It should be stressed that, for conditions
that are life-threatening, mortality is an important outcome to evaluate and, wherever possible, should be a primary
trial outcome, but this generally has substantial implications, with respect to the size of the trial.
Short-term outcomes are clearly attractive in that, if used as the outcome on which the design is based, the trial size
will be smaller and the duration shorter than if mortality were to be used. The danger is that the short-term measure in
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itself may not be of principal public health importance, and the effect of the intervention on that outcome may not
correlate well with the effect on more serious conditions. There is, for example, little point in measuring an antibody
response to infection if it bears no or little relation to the risk of disease. Conversely, in the relatively rare situations
where it is known that a short-term outcome is highly correlated with an outcome of greater public health
consequence (and is effectively a surrogate measure of the more important outcome), it will be more efficient to focus
the trial on the surrogate outcome.
In most circumstances, the appropriate outcome for determining the duration and size of the trial would be the most
serious consequence of the specific condition at which the intervention is aimed. However, it is not always feasible to
use such outcomes in a trial. For example, in a trial of a new measles vaccine in a HIC where death in someone who
has measles illness is rare, the onset of measles illness might be a sensible trial endpoint, rather than death from the
disease or total mortality. In contrast, in a country where a relatively high proportion of children with measles die,
death from measles might well be the outcome of choice. If mechanisms for establishing accurate diagnosis were
inadequate, total mortality might even be considered (especially as measles vaccine may reduce the risk of death
attributable to diseases other than measles).
Even in trials where total or cause-specific mortality are the primary trial endpoint, short-term ‘intermediate’
outcomes should also be collected as valuable secondary monitoring and explanatory outcomes, as laid out in the
impact model. They provide information, as the trial progresses, as to whether the trial is on target to meet its primary
goals and, if it is not on target, should help to identify what remedial action might be required. Also, if the trial does
not find a significant impact on its primary outcome, the ‘upstream’ outcomes may help provide an explanation for
why. For example, in a trial of the impact of insecticide-treated nets on malaria mortality, it would be important to
also measure net coverage and use, and data on the incidence of malaria illness and age-specific prevalence of malaria
parasitaemia by trial arm. When short-term outcomes are used in this way, any assumptions about the natural history
of the disease should be clearly thought through and stated in the trial protocol.
Definition of the primary trial outcome will have consequences for the duration of the trial. Prior information should
be available on the time needed for the intervention to affect the outcome. In some situations, such as the prevention
of liver cancer in adult life by hepatitis B vaccination in the first year of life, the final outcome measure may not be
observed for several decades. The need for monitoring of intermediate outcomes (such as the hepatitis B carriage rate)
then becomes even more important.
The choice of trial duration is critical for interventions whose impact does not increase linearly over time. For
example, the impact of a health education programme in schools to reduce sexual risk taking might be relatively
small, until a high proportion of the students have become sexually active. But even then, the impact might be small,
until both the students and their sexual partners (who might be several years older or younger) had been through the
programme. And finally, the impact may reach a ‘tipping point’ when enough people had been exposed to the
programme to change general social and sexual norms in the population as a whole. However, the choice of trial
duration is complicated by the fact that few funding agencies are keen to fund research projects that last more than 3–
5 years. A common strategy is to apply for initial funding for a 3- to 5-year trial that will be able to measure the
intervention’s impact on important intermediate outcomes but is large enough to measure the impact on the primary
trial outcomes if continued into a second trial follow-up phase, with the application for further funding based on the
results of the first phase.
A final and important point to stress in this section is that it is essential that attention is given to monitoring the
severity and frequency of adverse effects of an intervention. In their desire to assess the effectiveness of an
intervention, investigators often do not pay sufficient attention to finding and documenting adverse effects, which
may require additional effort and resources. In most situations, the future applicability of the conclusions drawn from
a trial will involve an assessment of the balance between positive and negative (adverse) effects.
6. Trial population
6.1. Criteria for selection of trial population
The criteria for selection of the population to be included in the trial depends primarily upon what condition the
intervention is directed against and upon the purpose of the trial. In general, the population will be chosen from an
area in which there is high incidence of the condition of interest, because the higher the incidence of the primary trial
outcome, the smaller the study population for the trial has to be. Exceptions are when the purpose of the trial is to
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determine the efficacy under special epidemiological circumstances or in special population groups such as in
pregnant women.
Good community and governmental co-operation and participation are also key factors in the successful conduct of a
trial. The trial area should be accessible at the times surveys are to be conducted (for example, during the rainy
season). Well-qualified and experienced field teams should be available or be able to be recruited. In addition, access
to high-quality clinical and laboratory facilities may be necessary for the trial. If required, entomological, behavioural
science, economic, and other appropriate disciplinary expertise should be available. Planning the trial will be much
simplified if baseline data are already available in the trial area.
If the trial design involves the repeated follow-up of members of the study population over several years, as will be
the case for many intervention trials, it is important to select a location for the trial in which substantial migration
into, or especially from, the area is unlikely to occur. Migration rates in excess of 10% per year are not uncommon in
many rural areas and may be considerably higher in urban or peri-urban settings. Unless the trial is conducted within a
demographic surveillance population, migration rates may well not be known in advance, so a rapid survey of a
sample of the proposed trial population may be useful to determine if a reasonable proportion of the population have
been resident in the area for several years.
The choice of trial population may affect the external validity of the trial results. For example, many micronutrient
trials are carried out in areas with high prevalence of the specific deficiency. The health impact from supplementation
in such areas is likely greater than what would be expected in areas where micronutrient deficits are less frequent,
which may represent the majority of areas where supplements will be used in the future.
6.2. Inclusion and exclusion criteria
In general, the trial population should be chosen to represent the group that would be the target for the intervention in
a potential future public health programme, if the intervention is found to be effective within the trial. Care should be
taken to define the target population. To the extent feasible, those included should be the persons for whom benefit is
likely to be the greatest, and those excluded should be the persons for whom benefit is likely to be minimal or indeed
who may be harmed. Specific inclusion and exclusion criteria should be developed for the trial. For example, because
the major morbidity and mortality associated with malaria in a holoendemic area are seen in infants and young
children, these groups are likely to be the focus of a major field trial of a malaria vaccine in such an area, though older
children and adults might be used in preliminary studies to test the safety of the vaccine in those who already have
some immunity or may be the focus of a vaccine trial where malaria transmission is much less intense.
In early trials of an explanatory nature, special groups at high risk may form the trial population, either to maximize
the potential effect, to ensure good compliance, or to facilitate the logistics. Valuable information concerning the
potential of the intervention can result, but the extent to which the results can be extrapolated to the general
population may be limited.
Exclusion criteria need to be carefully considered so as to eliminate subjects who may be put at greater risk by the
intervention or who have underlying conditions that may interfere with the assessment. Exclusion criteria should be
stated explicitly and unambiguously, before the trial begins. It is usual to exclude from trials those who are seriously
ill, those who are very old, those who are very young, and pregnant women, unless any of these are the specific target
group for the intervention. These groups are excluded either because it is considered that they are unlikely to derive
benefit from the intervention, or if they are thought to be more likely to be susceptible to possible adverse effects of
the intervention, or they are likely to suffer adverse events (AEs) which might incorrectly be associated with the
intervention if they are included. Ascertaining pregnancy is difficult, especially in its early stages, without specific
testing, and, in some trials, this may not be feasible. Sometimes all women of childbearing age are excluded from
trials, if it is thought that damage may be caused by the intervention to the fetus. Against this must be balanced the
potential benefit that the excluded groups may receive from the intervention. Also, if pregnant women or children, for
example, have been excluded from a trial that shows the intervention to be effective, resulting public health
programmes may consider it is inappropriate for them to receive the intervention, in case there are unforeseen risks to
them or because the safe and optimal dosage of any drugs involved are not known. As a result, it may be appropriate
to include them in later ‘bridging’ trials, with careful monitoring of pregnancy outcomes.
6.3. The size of the trial population
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Attention needs to be given to the required size of the trial, in terms of the precision of the effect estimates and of the
power to detect important differences. These aspects are discussed in detail in Chapter 5. It is important to allow for
the loss of power that results from group randomization if such a design is adopted (see Chapter 5, Section 6).
For interventions that are likely to be given to large numbers of individuals, if they are subsequently introduced into
disease control programmes, there are strong arguments in favour of designing trials of the interventions to also be
large not only to pick up any rare side effects, but also to obtain a relatively precise measure of their expected impact.
6.4. Compliance
Conclusions from a trial will be based on a comparison of the outcome measures adopted for the trial in those
allocated to the alternative intervention arms of the trial. Only a certain proportion of those allocated to a particular
intervention will receive that intervention effectively. Effective delivery of an intervention requires both that the
provider carries out the intervention procedure correctly and that the trial participants co-operate in the desired
fashion. In field trials, the provision of the intervention will usually be under the control of the investigator, but a
successful trial also requires the compliance of the participants, who are not under the control of the investigator, and
will depend on the understanding and co-operation of the community involved. Hence, the strong emphasis in this
manual on the importance of communication and feedback between the investigating team and the participating
communities has a pragmatic, as well as an ethical, basis.
In most trials, however, some participants will not fully comply, and the intervention procedure either will not be
carried out or it will not be done in an effective manner. For trials to determine the public health value of an
intervention (pragmatic trials), some degree of non-compliance may give a more realistic measure of effectiveness
than a tightly controlled trial in which every effort is made to ensure that the intervention is effectively delivered, but
for explanatory studies, in which an important objective may be to determine the maximum effect possible, every
effort should be made to keep compliance high. Wherever possible, the degree of compliance should be continually
monitored, at least on a sample basis. This might be done, for example, by doing urine or blood analyses to check that
the expected drug or nutritional supplement has actually been ingested. For intervention measures that are
administered sequentially over time or on a continuing ongoing basis, repeated specimens should be taken. In a trial to
measure the impact of introducing improved water supplies, for example, it will be important to measure the
proportion of the target population who actually access the improved water source. This is particularly relevant in
trials in which a health effect is mediated through a change in behaviour, as is the case in a breastfeeding promotion
trial with morbidity or mortality as endpoints. Documenting compliance with counselling—assessed through changes
in feeding practices—is essential.
A further aspect of compliance that is sometimes overlooked is that those in the ‘control’ arm of a trial, who are
allocated to routine care or placebo, may adopt the test treatment under study. For example, if health centres in some
villages are allocated to receive an intervention, such as offering voluntary medical male circumcision or improved
STD treatment, while those in other villages serve as controls, people in the control villages may go to the health
centres in the intervention villages to obtain the intervention. Monitoring for the possible occurrence of this latter
form of non-compliance (sometimes called ‘contamination’) is important. Care should also be taken in the
construction of the different treatment groups to minimize the opportunity for such contamination. In the circumcision
example, ensuring there is clear geographical separation of villages in the different arms of this trial by leaving a
‘buffer zone’ would be one means of minimizing contamination.
7. Implementation
7.1. Community acceptance
Critical to the conduct of a successful trial is that the trial population co-operates during the conduct of the trial and
takes up the intervention offered. They must feel a part of the trial and perceive it to be for the benefit of their
community. To ensure these aspects will require careful planning and investigation before the trial starts, including
appropriate discussion with, and explanation to, community leaders and potential participants. Feedback and
interaction should be continued throughout the course of the trial. These aspects are discussed in several chapters, and
especially in Chapters 6 and 9 and part of Chapter 15.
7.2. Feasibility studies and pilot testing
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Unless the acceptability and feasibility of implementing the intervention and the evaluation procedures that will be
used in the trial have already been tested locally, it is usually wise to conduct a smaller feasibility study in advance of
the main trial. The feasibility study may only include some aspects of the trial, such as the acceptability and feasibility
of delivering the intervention, or the feasibility of enrolling trial participants or of administering a questionnaire or
collection and testing of laboratory specimens. Whether or not such a feasibility study has been conducted, it is
essential that all the trial procedures are tested together in a pilot study, exactly as they will be applied in the actual
large-scale field trial. However, the pilot study should be conducted on a much smaller number of participants and
with enough time for the trial procedures to be modified in the light of the findings. Feasibility studies and pilot
studies are discussed in detail in Chapter 13.
7.3. Staff recruitment, training, and retention
The dedication and commitment of the staff employed to conduct a field research project are essential. This will
involve their careful selection, training, and then support. They must understand the importance of their role in the
trial and how it relates to that of others. The importance of high-quality work must be emphasized, and this must be
monitored throughout the trial (see Section 9 and Chapter 16). Trials of long duration present the additional challenge
of keeping staff motivated and performing at adequate levels of quality and avoiding excessive turnover. Open and
frank discussions with staff are essential, and benefits, such as regular increases in salaries over time, may help
motivation and retention.
7.4. Field organization
All aspects of field procedures should be planned in advance, and potential problems and solutions anticipated (for
example, in case of staff sickness or vehicle, computer, or laboratory equipment failure). The trial design must reflect
not only what is ideal, but also what can be done, given the constraints under which the trial must be conducted. These
aspects are considered in detail in Chapters 16 and 17. Issues relating to mapping and conducting a census of the trial
area are covered in Chapter 10.
8. Data handling
8.1. Data collection
A necessary part of most trials will be the collection of baseline (pre-intervention) data. These will include
identification information on participants, such as name, age, sex, place of residence, and information on other factors
that may influence the risk of occurrence of the outcome measures under study in the trial. Although randomization of
a large enough number of individuals, or clusters of individuals, should result in an approximately equal distribution
of all the important characteristics between trial arms, such baseline data, which should ideally include all known
confounders, can be used to check that this balance has actually occurred in practice. And if it has not, then it can also
be used to adjust for such imbalances in the trial analyses.
In addition, it may be important to collect general baseline data on the population where the trial is being carried out.
These may include not only the epidemiological characteristics of the population, but also the socio-economic,
cultural, political, health services, nutritional, and other relevant characteristics. Such contextual factors may be
essential to interpreting whether the trial’s results can be generalized to another setting.
Additional data will be collected during the course of the trial to monitor the application of the interventions and to
record information on the outcomes of interest. The conduct of a population census is described in Chapter 10, and
methods to obtain high-quality data at the start of a trial and during its course are described in Chapter 14. Obtaining
data using social or behavioural methods is outlined in Chapter 15, and for measuring the costs of the interventions is
outlined in Chapter 19. Of crucial importance in any trial is the proper measurement of the incidence of endpoints
against which the intervention is designed to protect, and these aspects are discussed in Chapter 12.
8.2. Data processing
Methods of coding, entering, and then managing computerized data collected in a trial are described in Chapter 20.
9. Quality control
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In most intervention studies, members of the population are invited to participate, the intervention is applied, perhaps
repeatedly, and the population is kept under surveillance, until the final trial outcomes are recorded. The quality of
each step in this process must be monitored. The two major reasons, which hardly need stating, are first to ensure that
each operation is being performed to an acceptable standard, and second to identify areas where attention is required.
A third reason is to be able to ascertain, at the end of a trial that failed to show anticipated effects, the possible reasons
for failure. The damage done by a misleading ‘negative’ result can be serious. The following are major aspects of
quality control (QC) that need attention.
9.1. The intervention
Regular monitoring of the delivery of the intervention should be an integral part of the design to ensure that there is
no change in the quality, as a trial goes on. For example, in a vaccination trial, continual review would be needed of
the quality of the vaccination techniques being used by fieldworkers and of the quality of the vaccine(s) used in the
intervention. For example, the potency of each batch of vaccine used should be assayed, together with monitoring of
the maintenance of any required cold chain. Particularly relevant for trials where the intervention includes case
management or counselling is monitoring the quality of these procedures through regular observation of a sample of
provider–client interactions.
Short-term endpoints may be used for monitoring the quality of the intervention. At the individual level, repeated
surveys of physiological measures of response to the intervention will provide an assessment of whether an effective
intervention agent has been delivered. Examples would be antibody levels against a vaccine or levels of a
micronutrient in serum. In trials including provider–client interactions, exit interviews with clients can be used to
monitor their understanding of the advice that was provided. Such evaluations may have to be done or be evaluated by
an independent trial monitor to ensure that those who will assess the main endpoints in the trial are kept blind—
whenever possible—to the identity of those in intervention and control groups.
9.2. Follow-up
For many intervention studies, the endpoints of interest may not emerge until a lengthy period after the start of the
intervention. It may not be necessary to keep the entire trial population under active observation, and this is often not
feasible (for example, cases might be detected, as they report to clinics, rather than by conducting periodic surveys of
the trial population), but it is essential that the trial is designed in such a way that losses to the trial population (for
example, cases who do not go to clinics) will not distort the conclusions. The follow-up rate should be monitored, in
order to identify potential problems at an early stage (for example, disgruntlement in a particular village or to identify
a fieldworker whose work quality is declining). If possible, the reasons that individuals are lost to follow-up should be
ascertained. Some losses may be inevitable, such as participants who die or who move out of the trial area, while it
may be possible to take remedial action to prevent others such as participants who withdraw their participation or who
are temporarily absent but could be found by repeated visits to their homes. The baseline characteristics of those who
are lost to follow-up should be compared with those of participants who remain in the trial, and this information
should be analysed to assess any effect that the losses might have on the interpretation of the results of the trial.
9.3. Assessment of trial outcomes
Mechanisms have to be established to ensure that the quality of information on all the trial outcomes is acceptable.
Ongoing monitoring is required to establish that the data on trial outcomes are maintaining acceptable quality and that
no biases are present in the way outcomes are recorded in different treatment arms. Attention needs to be paid to inter-
observer variation in the assessment of the outcomes and changes that may occur in this variation, as the trial
progresses.
9.4. Other field and laboratory procedures
QC should pervade all field activities, and the question as to how high quality is to be achieved and maintained should
be addressed specifically for all activities. This is discussed in most of the chapters that follow, and specifically in
Chapter 16, Section 7.
Laboratory procedures should be subject to constant scrutiny, and ‘blind’-coded duplicate samples or known positives
or negatives should be introduced into the workload regularly to monitor performance.
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In interview surveys, a proportion of respondents should be re-interviewed by a second interviewer, blind to the
results of the first interviewer, to check on the repeatability of the responses. If the questionnaire is long, the re-
interviews might focus on a subset of key questions, rather than repeating the full questionnaire, in order to avoid
undue demands on participants.
It is important that all involved in the trial accept and understand the need for constant checking and re-checking. This
is both so that any sanctions that are taken for repeated poor performance do not come ‘out of the blue’, but, more
importantly, as a way of encouraging all trial staff to maintain high quality at all times, because they know that errors
will be spotted reasonably quickly. On the other hand, errors are bound to occur, and their detection should usually
result in support and, where necessary, additional training, with reprimands being reserved for where there is evidence
of dishonesty or continual carelessness. Incentives or rewards to encourage high-quality work may be worthwhile.
All members of the field team are, and must be made to feel, important contributors to the research project. Feedback
of results and progress should be continuous and frequent, so that they can appreciate where their contribution fits into
the overall project. Neglect is a great stimulus to poor-quality work.
10. Analysis, monitoring, and reporting
10.1. Planning the main analyses
The main analyses that are expected to result from the trial should be developed in some detail, with the use of
dummy tables. Such an exercise is a great help when planning the trial, as it helps clarify exactly what data are
actually needed and highlights redundant data. All specific objectives should be tied to planned analyses.
10.2. Analyses during the trial
Analysing relevant data from a trial, as they accumulate during the trial, is an important way of monitoring the
satisfactory progress of a trial. Administrative analyses of the numbers of participants recruited each day or week and
of the data collected by different fieldworkers are important for QC. A running tally should be kept of the numbers of
participants experiencing the various trial endpoints to verify that the estimates of incidence rates used to plan the size
of the trial were appropriate. Ideally, the investigators will be blind with respect to which interventions have been
allocated to which participants, but differences between the different interventions might be analysed by a data and
safety monitoring committee (as discussed in Section 10.3). Other aspects of interim analyses are discussed in
Chapter 5, Section 7.1 and Chapter 7, Section 4.1.3.
Increased reliance on the use of smart phones or personal data assistants (PDAs) to record data when interviewing
participants facilitates real-time data quality checks and analyses. Considerable ahead-of-time preparation and
planning, however, are necessary, in order to programme devices to be able to produce such analyses regularly.
Interim reports, based on such ongoing analyses, may be required during the course of a trial by national authorities
and by the trial’s funding agency, in order to check that the original proposal is being adhered to and that the
assumptions underlying the trial design were correct.
10.3. Data and Safety Monitoring Committee
For large trials, it is advisable for the investigators to set up an independent DSMC. Such a committee generally has
access to selected unblinded data during the course of a trial and, for example, will conduct analyses to monitor
whether there are an unacceptable number of adverse events (AEs) associated with an intervention. In such
circumstances, the committee may recommend changes to the design of the trial or, in more extreme cases, that the
trial be stopped, either temporarily or permanently.
The DSMC might also be charged with conducting interim analyses of the trial with respect to the primary endpoint,
so that if the efficacy of intervention is substantially lower or substantially higher than expected, changes to the trial
design, including early stopping, might be recommended.
The roles and functioning of DSMCs are discussed in Chapter 7.
The most important function is usually to hold the randomization code for the trial and to monitor the results of the
trial, both in terms of effectiveness and safety, as they accumulate. If there is evidence of a substantially increased risk
of adverse reactions associated with any of the interventions under study, the committee would have the power to
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advise the Trial Steering Committee to stop further recruitment. Similarly, if evidence accumulates that one
intervention is substantially better than the others (or one is substantially worse), the committee would usually
recommend that the trial be ended or that at least one of the trial arms is discontinued. In blinded trials, a major
advantage of these functions being undertaken by an independent committee is that the investigators can remain blind
to the randomization codes, which is an important way of ensuring unbiased assessment of the trial endpoints. But,
even where the trial is not blinded, it still has the considerable advantage of ensuring that the recommendation of
stopping or continuing a trial is as objective as possible, because stopping a trial early usually has considerable
logistic implications and may not be popular with the investigators, staff (who may even need to be laid off early), or
participants.
The circumstances in which a trial will be prematurely ended should be carefully considered when the trial is being
designed, and the DSMC should be party to such discussions. It will not be possible to predict all possible situations
that may cause a decision to be taken to end a trial, but this should be done to the extent possible. In particular, there
should be consideration as to how large a difference may be apparent between the interventions, with respect to their
impact on specific endpoints, before it is decided to end the trial. In some circumstances, it may be important to go on
beyond the point where statistical significance is reached. These issues are discussed in Chapter 5, and there are also
ethical considerations which are discussed in Chapter 6.
The DSMC might also set up independent QC checks on trial procedures and, for example, may arrange to review the
diagnoses of all cases of the diseases of interest arising in the trial (which should be done, of course, ‘blind’ to
knowledge of the randomization codes).
The committee usually works on a pro bono basis and does not have auxiliary staff. If its activities will require QC
checks or diagnostic reviews, it may be necessary to budget for these activities when preparing the protocol.
In some trials, the DSMC may consist of one person, sometimes called the ‘clinical monitor’.
10.4. Analysis methods
The analysis of a large field trial will usually be a complex undertaking and will usually require the involvement of a
professional statistician, sometimes under supervision of a senior statistician or epidemiologist. It is not feasible in a
manual of this kind to detail all of the analysis methods that it might be appropriate to employ in different trials.
However, in Chapter 21 an outline is given of the main methods of analysis that are likely to be employed. It is
included as it summarizes relevant methods that are not covered as comprehensively in the most basic
epidemiological texts or books on medical statistics.
10.5. Reporting results
Once a field trial has been completed and the results analysed, it is essential that the results and their implications are
made available to the scientific community, to those who participated in the trial, and to those responsible for
designing and implementing regional and national disease control strategies. These aspects are discussed in Chapter
23.
10.6. Further studies
Many trials will provoke questions amenable to further research. One example might be if a trial of a hookworm
vaccine shows that it provokes good specific antibody- and cell-mediated immune responses and reduces the
incidence of infection by 80% but is associated with prohibitive adverse reactions, further studies may well be needed
to explore which antigens are causing the adverse reactions and whether removing these will also reduce the vaccine’s
effectiveness against hookworm.
Alternatively, if a trial of traffic-calming measures in one city shows that they are highly effective in reducing road
traffic accidents, questions may well arise on how best to implement similar measures in other settings and/or to
monitor the effectiveness of such interventions when implemented on a wide scale and over a long period of time.
Such studies are often called Phase IV studies, as they evaluate interventions in real-world settings after the Phase III
trial has been completed. These are discussed in Chapter 22.
11. The ‘SPIRIT’ checklist for standard protocol items for clinical trials
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Nearly all intervention trials will need to have a protocol developed, which serves as the basis for trial planning,
conduct, and reporting. Before a trial starts, it is recommended or, in many cases, required that the protocol is
deposited in a trial register (see Chapter 7, Section 5). Until recently, there has not been specific guidance as to
exactly what items should be included in such a protocol. However, such guidance has recently been published (Chan
et al., 2013a; Chan et al., 2013b) as a component of the EQUATOR project (Enhancing the QUAlity and
Transparency Of health Research) (<http://www.equator-network.org/>). The publications include a 33-item checklist,
the so-called SPIRIT (Standard Protocol Items: Recommendations for Intervention Trials) 2013 checklist, which is
reproduced in Table 4.1. This gives a useful outline of how a trial protocol might be organized, bearing in mind the
issues we have discussed in this chapter. Readers should refer to the SPIRIT website (<http://www.spirit-
statement.org/>) for the most recent version.
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The ‘stepped wedge’ trial design used to evaluate the impact of hepatitis B vaccination on liver cancer rates in The
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2a Trial identifier and registry name. If not yet registered, name of intended registry
2b All items from the World Health Organization Trial Registration Data Set
Protocol
version
3 Date and version identifier
Funding 4 Sources and types of financial, material, and other support
Roles and
responsibilities
5a Names, affiliations, and roles of protocol contributors
5b Name and contact information for the trial sponsor
5c Role of study sponsor and funders, if any, in study design; collection, management, analysis,
and interpretation of data; writing of the report; and the decision to submit the report for
publication, including whether they will have ultimate authority over any of these activities
5d Composition, roles, and responsibilities of the coordinating centre, steering committee,
endpoint adjudication committee, data management team, and other individuals or groups




6a Description of research question and justification for undertaking the trial, including
summary of relevant studies (published and unpublished) examining benefits and harms for
each intervention
6b Explanation for choice of comparators
Objectives 7 Specific objectives or hypotheses
Trial design 8 Description of trial design, including type of trial (for example, parallel group, crossover,
factorial, single group), allocation ratio, and framework (for example, superiority,
equivalence, non-inferiority, exploratory)
METHODS: PARTICIPANTS, INTERVENTIONS, AND OUTCOMES
Study setting 9 Description of study settings (for example, community clinic, academic hospital) and list of
countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility
criteria
10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study
centres and individuals who will perform the interventions (for example, surgeons,
psychotherapists)
Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and
when they will be administered
11b Criteria for discontinuing or modifying allocated interventions for a given trial participant
(for example, drug dose change in response to harms, participant request, or
improving/worsening disease)
11c Strategies to improve adherence to intervention protocols and any procedures for monitoring
adherence (for example, drug tablet return, laboratory tests)
11d Relevant concomitant care and interventions that are permitted or prohibited during the trial
*





Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (for
example, systolic blood pressure), analysis metric (for example, change from baseline, final
value, time to event), method of aggregation (for example, median, proportion), and time
point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm
outcomes is strongly recommended
Participant
timeline
13 Time schedule of enrolment, interventions (including any run-ins and washouts),
assessments, and visits for participants. A schematic diagram is highly recommended (see
figure at <http://annals .org/article .aspx?articleid=1556168>)
Sample size 14 Estimated number of participants needed to achieve study objectives and how it was
determined, including clinical and statistical assumptions supporting any sample size
calculations
Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size




16a Method of generating the allocation sequence (for example, computer-generated random
numbers) and list of any factors for stratification. To reduce predictability of a random
sequence, details of any planned restriction (for example, blocking) should be provided in a




16b Mechanism of implementing the allocation sequence (for example, central telephone;
sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the
sequence, until interventions are assigned




17a Who will be blinded after assignment to interventions (for example, trial participants, care
providers, outcome assessors, data analysts), and how
17b If blinded, circumstances under which unblinding is permissible and procedure for revealing
a participant’s allocated intervention during the trial
METHODS: DATA COLLECTION, MANAGEMENT, AND ANALYSIS
Data collection
methods
18a Plans for assessment and collection of outcome, baseline, and other trial data, including any
related processes to promote data quality (for example, duplicate measurements, training of
assessors) and a description of study instruments (for example, questionnaires, laboratory
tests), along with their reliability and validity, if known. Reference to where data collection
forms can be found, if not in the protocol
18b Plans to promote participant retention and complete follow-up, including list of any outcome
data to be collected for participants who discontinue or deviate from intervention protocols
Data
management
19 Plans for data entry, coding, security, and storage, including any related processes to promote
data quality (for example, double data entry; range checks for data values). Reference to
where details of data management procedures can be found, if not in the protocol
Statistical
methods
20a Statistical methods for analysing primary and secondary outcomes. Reference to where other
details of the statistical analysis plan can be found, if not in the protocol
20b Methods for any additional analyses (for example, subgroup and adjusted analyses)
20c Definition of analysis population relating to protocol non-adherence (for example, as
randomized analysis) and any statistical methods to handle missing data (for example,
multiple imputation)
METHODS: MONITORING








21a Composition of Data Monitoring Committee (DMC); summary of its role and reporting
structure; statement of whether it is independent from the sponsor and competing interests;
and reference to where further details about its charter can be found, if not in the protocol.
Alternatively, an explanation of why a DMC is not needed
21b Description of any interim analyses and stopping guidelines, including who will have access
to these interim results and make the final decision to terminate the trial
Harms 22 Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported
AEs and other unintended effects of trial interventions or trial conduct
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be




24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval
Protocol
amendments
25 Plans for communicating important protocol modifications (for example, changes to
eligibility criteria, outcomes, analyses) to relevant parties (for example, investigators,
REC/IRBs, trial participants, trial registries, journals, regulators)
Consent or
assent
26a Who will obtain informed consent or assent from potential trial participants or authorized
surrogates, and how (see item 32)
26b Additional consent provisions for collection and use of participant data and biological
specimens in ancillary studies, if applicable
Confidentiality 27 How personal information about potential and enrolled participants will be collected, shared,
and maintained, in order to protect confidentiality before, during, and after the trial
Declaration of
interests
28 Financial and other competing interests for principal investigators for the overall trial and
each study site
Access to data 29 Statement of who will have access to the final trial dataset and disclosure of contractual
agreements that limit such access for investigators
Ancillary and
post-trial care
30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer
harm from trial participation
Dissemination
policy
31a Plans for investigators and sponsor to communicate trial results to participants, health care
professionals, the public, and other relevant groups (for example, via publication, reporting in
results databases, or other data sharing arrangements), including any publication restrictions
31b Authorship eligibility guidelines and any intended use of professional writers










33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or
molecular analysis in the current trial and for future use in ancillary studies, if applicable
Reproduced with permission of the SPIRIT group. It is strongly recommended that this checklist be read in conjunction with the SPIRIT
2013 Statement (Chan et al., 2013a), in order to fully understand the scope and context of the checklist. It is important to note that this is
a minimum list of items, and certain trial protocols may warrant the inclusion of additional items. This table is distributed under the
terms of the Creative Commons Attribution Non Commercial 4.0 International licence (CC-BY-NC), a copy of which is available at
http: //creativecommons .org/licenses/by-nc/4.0/.
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